PTEN and breast cancer: We see by the GR50 metric that PTEN mutant and wild-type breast cancer cells exhibit a highly significant difference (p = 0.0033) in sensitivity to lapatinib treatment, which is not found by IC50 value (p = 0.12; Step 9).